Repligen closed at $178.20 on Nov 4, down 0.04%, 8.4% below its 52-week closing high. Volume of 1.1M shares was 0.74× its 20-day average (below normal).
Split-adjusted performance: +1.9% over one month, +41.7% over six months, +18.7% over one year.
In the quarter ended Sep 30, 2026, revenue was $209.31M, up 10.9% from a year earlier, with a net margin of -18.4%.
Short interest was 7.1M shares at the Oct 15 settlement, down 5.8% from the prior report (12.8% of float, 4.9 days to cover).
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies.
What is RGEN's market cap?
$11.31B, based on the Nov 4 close of $178.20.
Does Repligen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RGEN is sold short?
7.1M shares, 12.8% of float, as of Oct 15, 2026.
What sector is RGEN in?
Healthcare, in the Biotechnology industry.
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
